Last week at the #ASGCT Annual meeting in Boston, Hélène Tran shared how our teams are leveraging #AI to accelerate the development of antisense oligonucleotide therapies in #neurology. A great example of how we are combining science and technology to address high unmet needs. Read the full recap here: https://lnkd.in/eb8AuE-X #Boston
About us
Servier is a privately held international pharmaceutical company headquartered in France with a passion for innovation that has improved patients’ lives around the world. With $4.7 billion in annual sales Servier operates in almost 150 countries worldwide across five therapeutic categories including oncology, cardiovascular, immuno-inflammatory, neuroscience and diabetes. Servier is founded on the principle of serving and governed by an independent non-profit foundation. With this unique operating model, the company can be deliberate about putting patients ahead of profits. In fact, Servier re-invests 25 percent of revenue into research and development each year. Servier is committed to therapeutic progress to serve patient needs and strives to provide future generations with a world where quality healthcare is available and accessible to all. See our community guidelines here: https://www.servier.us/community-guidelines To report a suspected adverse event with a Servier product, please visit: https://www.servier.us/contact-us
- Website
-
https://www.servier.us/
External link for Servier Pharmaceuticals
- Industry
- Pharmaceutical Manufacturing
- Company size
- 201-500 employees
- Headquarters
- Boston , MA
- Type
- Nonprofit
Locations
-
Primary
Get directions
200 Pier Four Boulevard
Boston , MA 02210, US
Employees at Servier Pharmaceuticals
Updates
-
Servier is committed to supporting long-term innovation and translating science into meaningful medicines for children and families. Through our One Innovation Engine, we bring together internal R&D capabilities, external partnerships, diverse perspectives, and cutting‑edge technologies to drive innovation and strengthen our pipeline. Learn more about our approach: https://lnkd.in/esSSHFz3
-
It was a productive week in D.C. for the New England Council Washington Leaders’ Conference! At #Servier, we always value opportunities to engage in conversations helping shape the future of innovation and patient care. Thank you to all New England Council conference organizers for putting on another engaging event. #NewEnglandCouncil #WashingtonLeadersConference
-
-
We were honored to host the FACCNE ⎮ French-American Chamber of Commerce, New England 2026 French-American Business Awards Pitch Competition here in our Boston office! It was inspiring to see the energy, collaboration, and ambition of innovators shaping the life sciences industry and beyond. We’re grateful for our continued partnership with FACCNE and the chance to support initiatives like this. #FACCNE #FABAwards #LifeSciences #Innovation
-
-
#Servier today announced that the U.S. Food and Drug Administration (FDA) has granted #breakthrough therapy designation to our investigational therapy for the treatment of patients with #AdenoidCysticCarcinoma (ACC). This significant step forward in our #oncology pipeline brings Servier closer to advancing the treatment landscape for patients living with ACC, a rare and difficult-to-treat cancer for which there are currently no approved treatments for advanced or metastatic disease. Read the full announcement here: https://lnkd.in/edJZNT8i
-
-
We are pleased to announce that Day One, now part of Servier Group, has completed enrollment for the Phase 3 FIRELFY-2 trial, the largest study ever conducted in front-line pediatric low-grade glioma (pLGG).
Today we've announced the completed enrollment in the FIREFLY-2 clinical trial, evaluating our medicine as a front-line treatment for pediatric low-grade glioma (pLGG). This is another step forward in our work to evolve the pLGG treatment paradigm and ultimately establish a new standard of care for patients newly diagnosed with pLGG. Read more: https://lnkd.in/gjnfSTN7
-
-
Digital transformation goes further than implementing digital tools. It requires: - Strategic alignment of internal capabilities - Global partnerships - The right incentives to promote adoption. At Servier, our 2030 ambition is clear: leveraging #data and #AI to attempt to double our probability of success in #drugdiscovery and significantly reduce time-to-market. By combining in-house expertise with a balanced ecosystem of partners, we are turning technology into a tangible force multiplier for our R&D. Discover how Servier is scaling AI from discovery to delivery: https://lnkd.in/d-DKcRFz #AI #Innovation #Servier
-
-
We’re expanding our Hematology sales team and are seeking multiple Senior Oncology Consultants across the U.S. In this role, you’ll join a highly collaborative team dedicated to supporting the delivery of innovative therapies and advancing Servier’s vision of transforming patients’ lives through science. If you bring strong commercial expertise, a team‑oriented mindset, and a passion for making a meaningful impact, we encourage you to explore these opportunities. Join Abbey and the Servier Hematology Sales team. Visit our Careers page to learn more: https://lnkd.in/e9CaYpxA #Servier #Hiring #Hematology
-
-
We’re proud to amplify #BrainTumorAwarenessMonth. Pediatric brain tumors remain some of the most difficult to treat, but through our combined expertise and shared commitment to patients, we are strengthening our ability to deliver the research, innovation, and support these children and families deserve. Join us as we #GoGrayInMay.
Every day, children and families face the life-changing reality of a brain tumor diagnosis, the most common solid tumor in pediatric patients and some of the hardest to treat. During #BrainTumorAwarenessMonth, we’re committed to shining a light on the profound impact brain tumors have on children and their families, and the crucial need for more research, treatment options, and support. Join us in raising awareness as we #GoGrayInMay.
-
-
It’s great to see the team at #ASPHO26, the leading conference for the pediatric oncology community. If you’re in Minneapolis, stop by the booth to connect with the team!
Our team is excited to attend #ASPHO26 and to join the pediatric oncology community in discussing the latest innovations shaping pediatric drug development. Attending the meeting? Stop by booth 324 to connect with our team next week.
-